FDA Clears NUZ-001 for Entry into HEALEY ALS Platform Trial
- Written by PR Newswire
Highlights:
- FDA has completed their review of the Neurizon NUZ-001 regimen to the HEALEY ALS Platform Trial Master Protocol
- This marks the official entry of NUZ-001 as Regimen I in the HEALEY ALS Platform Trial
- Next steps include obtaining single IRB approval, site initiations and clinical start-up activities ahead of commencement of patient...
Read more: FDA Clears NUZ-001 for Entry into HEALEY ALS Platform Trial
